NIH to Test Pfizer's Paxlovid for Long COVID
The National Institutes of Health's $1 billion RECOVER Initiative has picked Pfizer Inc's antiviral drug Paxlovid as the first treatment it will study in patients with long COVID, organizers of the study said on Thursday.
Reuters Health Information
source https://www.medscape.com/viewarticle/983150?src=rss
Reuters Health Information
source https://www.medscape.com/viewarticle/983150?src=rss
Comments
Post a Comment